Aptose Biosciences Inc. APTO NASDAQ

Aptose Biosciences Inc. (APTO) generated $-2.8M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $0.00, free cash flow was $-2.8M.

Cash conversion ratio was 0.36x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (0/100, Fail) — weak cash flow raises concerns about debt servicing
• MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (?/100) — Cash conversion ratio was 0.36x suggests some earnings are non-cash items

Overall SharesGrow Score: 43/100 with 2/7 criteria passed.